Novartis AG’s program to help needy patients or those living in rural areas pay for travel and lodging costs associated with administration of its Kymriah will not incur penalties or sanctions under the US federal anti-kickback statute, the Department of Health and Human Services Office of Inspector General has concluded.
“Although the arrangement could potentially generate prohibited remuneration under the anti-kickback statute if the requisite intent to induce or reward...







